Zhejiang Benli Technology Co., Ltd.

301065

CNE100004RL8

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 16/07/2024 BST			5-day change	1st Jan Change
16.16 ^CNY	-3.12%		+5.07%	-28.97%

07-02	Tranche Update on Zhejiang Benli Technology Co., Ltd.'s Equity Buyback Plan announced on February 6, 2024.	CI
06-14	Zhejiang Benli Technology Co., Ltd. Announces 2023 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 20 June 2024	CI

Tranche Update on Zhejiang Benli Technology Co., Ltd.'s Equity Buyback Plan announced on February 6, 2024.

July 02, 2024 at 11:04 am

From April 1, 2024 to June 30, 2024, the company has repurchased 370,200 shares, representing 0.36% for CNY 6.59 million. With this, the company has completed the repurchase of 2,847,362 shares, representing 2.69% for CNY 50 million under the buyback announced on February 6, 2024.

Latest news about Zhejiang Benli Technology Co., Ltd.

Tranche Update on Zhejiang Benli Technology Co., Ltd.'s Equity Buyback Plan announced on February 6, 2024.	07-02	CI
Zhejiang Benli Technology Co., Ltd. Announces 2023 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 20 June 2024	06-14	CI
Zhejiang Benli Technology Co., Ltd. Proposes Final Cash Dividend for the Year 2023	04-23	CI
Zhejiang Benli Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-23	CI
Tranche Update on Zhejiang Benli Technology Co., Ltd.'s Equity Buyback Plan announced on February 6, 2024.	04-01	CI
Zhejiang Benli Technology Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.	02-06	CI
Zhejiang Benli Technology Co., Ltd. authorizes a Buyback Plan.	02-05	CI
Zhejiang Benli Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	26/10/23	CI
Certain A Shares of Zhejiang Benli Technology Co., Ltd. are subject to a Lock-Up Agreement Ending on 14-SEP-2023.	13/09/23	CI
Zhejiang Benli Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	28/08/23	CI
Zhejiang Benli Technology Co., Ltd. Implements Final Profit Distribution of A Shares for the Year 2022, Payable on June 16, 2023	09/06/23	CI
Zhejiang Benli Technology Co., Ltd. Approves the Cash Dividend for the Year 2022	19/05/23	CI
Zhejiang Benli Technology Co., Ltd. Proposes Final Cash Dividend for the Year 2022	27/04/23	CI
Zhejiang Benli Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	26/04/23	CI
Zhejiang Benli Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	26/04/23	CI
Zhejiang Benli Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	26/10/22	CI
Zhejiang Benli Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	28/08/22	CI
Linhai Benli Technology Co., Ltd. announced that it expects to receive CNY 150 million in funding from Zhejiang Benli Technology Co., Ltd.	16/06/22	CI
Zhejiang Benli Technology Co., Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on June 16, 2022	08/06/22	CI

Chart Zhejiang Benli Technology Co., Ltd.

Duration

Period

Chart Zhejiang Benli Technology Co., Ltd.

More charts

Company Profile

Zhejiang Benli Technology Co Ltd is a company engaged in the research and development (R&D), production and sales of pharmaceutical intermediates, pesticide intermediates and new material intermediates. The Company's products mainly include 801 products, 1201 products, 1501 products and 1701 products. The Company's products are mainly used in quinolone active pharmaceutical ingredients (APIs), pesticides, fungicides, pesticides, herbicides, photoinitiators, pharmaceutical cephalosporins and other fields. The Company's products have been exported to foreign markets such as India and Japan.

Sector

Pharmaceuticals

Calendar

29/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ZHEJIANG BENLI TECHNOLOGY CO., LTD.	-28.97%	230M
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+31.64%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ASTRAZENECA PLC	+15.51%	247B
NOVARTIS AG	+16.72%	228B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B